Intraoperative Imaging Techniques in Oncology
Imaging-based procedures have become well integrated into the diagnosis and management of oncological patients and play a significant role in reducing morbidity and mortality rates. Here we describe the established and upcoming surgical oncological imaging techniques and their impact on cancer management. (Source: Clinical Oncology)
Source: Clinical Oncology - January 10, 2024 Category: Radiology Authors: S.S. Vulasala, P. Sutphin, P. Shyn, S. Kalva Source Type: research
OncoFlash –Research Updates in a Flash! (Feb 2024)
Preoperative Treatment of Locally Advanced Rectal Cancer: PROSPECT Randomised Phase III clinical trial. Deborah Schrag et al. N Eng J Med, 2023 [1]. (Source: Clinical Oncology)
Source: Clinical Oncology - January 9, 2024 Category: Radiology Authors: S. Parikh, K. Thippu Jayaprakash Source Type: research
RCR Meetings
(Source: Clinical Oncology)
Source: Clinical Oncology - January 9, 2024 Category: Radiology Source Type: research
Drug Appraisal Recommendations in Urological Oncology and Impact on Cancer Treatment Unit Visits at Sussex Cancer Network – 10-year Update
Purpose: Systemic treatment of solid tumours and clinical outcomes have significantly improved over the past two decades since the development and establishment of new cancer therapies [1,2]. The launch of the Cancer Drug Fund in 2016 enabled wider and faster access to cancer drugs [3]. At present, 78% of cancer drug appraisal recommendations are positive. Over the past 10 years, 8 new cancer drugs and 9 new indications have been recommended by NICE in urology, particularly in prostate and renal cancer [4 –8]. (Source: Clinical Oncology)
Source: Clinical Oncology - December 21, 2023 Category: Radiology Authors: K. Eremeishvili, P. Savage Source Type: research
Enhancement and Size-based Response Criteria for Evaluating Tyrosine Kinase Inhibitor Dosing Strategy in Metastatic Renal Cancer: Prospective Imaging Study from the UK STAR Trial
Purpose: Metastatic renal cancer (mRCC) is highly vascular. Reduction in vascularization precedes size regression on treatment [1]. Alternative response criteria, which include tumour enhancement change (a surrogate for vascularity), may improve selection of responding patients, over size-based RECIST, for tyrosine kinase inhibitor (TKI) treatment breaks [2,3]. The aim was to assess the association of computed tomography (CT) enhancement/size response categorisation with overall (OS) and progression-free survival (PFS). (Source: Clinical Oncology)
Source: Clinical Oncology - December 21, 2023 Category: Radiology Authors: T. Manickavasagar, C. Kelly-Morland, T.M. Wah, P. Nathan, J. Brown, V. Goh Source Type: research
Bone Health Management in Advanced Prostate Cancer: a Survey of UK Genitourinary Healthcare Professionals (GU HCPs)
Purpose: Protecting and improving bone health in patients with locally advanced and metastatic prostate cancer (PC) is increasingly being recognised as important to manage due to androgen-deprivation therapy (ADT)-related bone density loss and associated threat of osteoporosis and fractures, as well as skeletal-related complications from bone metastases [1 –3]. Unfortunately, there is currently no standard practice in the UK. We created a survey to understand the current practice amongst UK GU HCPs. (Source: Clinical Oncology)
Source: Clinical Oncology - December 21, 2023 Category: Radiology Authors: C. Navarro-Rodriguez, D. Manoharan, R. McMenemin, R. Pearson, A. Birtle, H. Payne, X.Y. Jiang Source Type: research
STAMPEDE2 Trial: a Survey on National Variations in Access to Novel Imaging in Metastatic Prostate Cancer and Implications for Trial Conduct
Purpose: The forthcoming STAMPEDE2 trial has three comparisons in metastatic hormone-sensitive prostate cancer (mHSPC). We aim to determine clinical practices across current trial sites in relation to imaging. (Source: Clinical Oncology)
Source: Clinical Oncology - December 21, 2023 Category: Radiology Authors: H. Abdel-Aty, L. O ’Shea, C. Amos, L.C. Brown, E. Grist, G. Attard Source Type: research
Is the Addition of Pelvic Nodal Irradiation Beneficial in Postoperative Salvage Radiotherapy for Prostate Cancer?
Purpose: Salvage radiotherapy (RT) to the prostate bed (PBRT) post-prostatectomy is well established [1]. The SPPORT trial [2] recently demonstrated that addition of pelvic nodal radiotherapy (PLNRT) may improve outcomes further. We aimed to retrospectively determine if nodal RT improved outcomes. (Source: Clinical Oncology)
Source: Clinical Oncology - December 21, 2023 Category: Radiology Authors: A. Batty, S.O. Bokhari, J. Doherty, H. Wong, I. Syndikus, R. Walshaw Source Type: research
Are Outcomes of Metastatic NSGCT at the Beatson West of Scotland Cancer Centre (BWOSCC) Comparable with the Updated IGCCC Prognostication Model?
Purpose: Outcomes for metastatic non-seminomatous germ cell tumours (NSGCT) have improved in the last 20 years, leading the International Germ Cell Cancer Collaborative Group (IGCCCG) to update their prognostication model in 2021 from the original model published in 1997 [1,2]. This project was designed to compare the survival outcomes of the Beatson West of Scotland Cancer Centre (BWOSCC) and the updated prognostication model in order to validate its use in our patient population. (Source: Clinical Oncology)
Source: Clinical Oncology - December 21, 2023 Category: Radiology Authors: L. Cammaert, S. Duncan, C. Boyle, A. Peters, J. White Source Type: research
Metastatic Renal Cell Carcinoma: Real-world Data from a District General Hospital
Purpose: Modern treatment options for metastatic renal cell carcinoma (mRCC) have substantially improved outcomes and life expectancy. These real-world data provide an insight into first-line treatment choices and outcomes in a non-academic centre. (Source: Clinical Oncology)
Source: Clinical Oncology - December 21, 2023 Category: Radiology Authors: L. Gray, S.T. Han, D. Muthukumar Source Type: research
Clinical Outcomes in a Locally Advanced Non-metastatic Prostate Cancer Presenting with Low PSA at Diagnosis
Purpose: To determine clinical outcomes for men with locally advanced prostate cancer (LAPCa) presenting with low serum prostate-specific antigen (PSA). (Source: Clinical Oncology)
Source: Clinical Oncology - December 21, 2023 Category: Radiology Authors: M. Haris, P. Maitre, J. Logue, J. Wylie, P. Hoskin, A. Choudhury Source Type: research
Real-world Study of Transdermal Oestradiol in Metastatic Prostate Cancer
Purpose: To assess the real-world safety and efficacy of transdermal oestradiol in metastatic prostate cancer. (Source: Clinical Oncology)
Source: Clinical Oncology - December 21, 2023 Category: Radiology Authors: H. Jaumdally, D. Hanna, J. Shamash Source Type: research
Correlation of Radiological and Pathological Staging in Early Prostate Cancer Treated with Robot-assisted Laparoscopic Prostatectomy
Purpose: To assess concordance of radiological and pathological staging in patients undergoing radical robot-assisted laparoscopic prostatectomy (RALP) [1]. (Source: Clinical Oncology)
Source: Clinical Oncology - December 21, 2023 Category: Radiology Authors: B. Kalra, A. Singh, A. Pathmanathan, S. Hazell, D. Cahill, A. Tree Source Type: research
REMAP: Response Evaluation in Metastatic Renal Cell Cancer (mRCC) using 18F-FDG PET/MRI
Purpose: Size change is used on computed tomography (CT) to assess treatment response in metastatic renal cell cancer (mRCC) but has limitations that functional imaging using 18F-fluorodeoxyglucose positron emission tomography/magnetic resonance imaging (18F-FDG PET/MRI) may address. This exploratory study aimed to assess the feasibility of 18F-FDG PET/MRI in mRCC to assess disease activity and heterogeneity. (Source: Clinical Oncology)
Source: Clinical Oncology - December 21, 2023 Category: Radiology Authors: T. Manickavasagar, C. Kelly-Morland, S. Rudman, D. Crawley, G. Cook, V. Goh Source Type: research
Biochemical Control after HDR Prostate Brachytherapy Boost for T3b Cancer: the Stokes Centre for Urology Experience
Purpose: High dose rate prostate brachytherapy (HDR-PB) allows dose escalation after external beam radiotherapy (EBRT) and androgen deprivation therapy (ADT) and is an effective treatment for patients with high-risk prostate cancer [1,2]. The purpose of this study is to present the experience of the Stokes Centre for Urology with HDR-PB in T3b disease, looking at biochemical control. (Source: Clinical Oncology)
Source: Clinical Oncology - December 21, 2023 Category: Radiology Authors: M. Metawe, S. Uribe-Lewis, S. Otter, C. Mikropoulos, C. Perna, S. Langley Source Type: research
